A potential clinical relevance of re-biopsy was obtained in 14 out of the re-biopsied 31 patients (45%); in fact, in the 14 patients in which a change from PD-L1 TPS negative to positive was highlighted, it was possible to administer Durvalumab maintenance (one patient was unable to take Durvalumab due to concurrent reactivated tuberculosis). Here, CD274 is linked to tuberculosis.